DIA and FDA have collaborated on bringing advancements in oligonucleotide-based therapeutic product development to industry professionals.
Horsham, PA (PRWEB) March 22, 2012
DIA, in collaboration with FDA, will host Oligonucleotide-based Therapeutics 2012: Leveraging Regulatory and Industry Knowledge for Future Advancements from April 16-18 in Washington, DC. This conference will bring the latest innovations on oligonucleotide-based therapeutic products to industry professionals.
Session topics will include:
- Chemistry, Manufacturing, and Controls (CMC)
- Clinical Development
- Oligonucleotide Safety
- Delivery methods
- Non-clinical assessments
“DIA and FDA have collaborated on bringing advancements in oligonucleotide-based therapeutic product development to industry professionals,” says Scientific Advisory Committee Member Cindy Berman, PhD. “Informing, educating, and sharing the latest topics will assist industry professionals in staying at the forefront of oligonucleotide-based knowledge. We aim to support drug development and clinical advances in therapeutic targets, trial design, and safety.”
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related medical products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India and Beijing, China. http://www.diahome.org.